title: Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
authors.forename: Maria
authors.initials: M
authors.lastname: Perera
authors.forename: Alexia
authors.initials: A
authors.lastname: Suarez
authors.forename: Hugo
authors.initials: H
authors.lastname: Luzardo
authors.forename: Jezabel
authors.initials: J
authors.lastname: Lopez
authors.forename: Teresa
authors.initials: T
authors.lastname: Molero
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D004351:Drug Resistance; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007116:Immunization, Passive; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications; D008875:Middle Aged; D009203:Myocardial Infarction / Q000601:surgery; D011241:Prednisone / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D011961:Receptors, Fc / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D000069283:Rituximab; D015607:Stents; D034061:Thrombopoiesis / Q000187:drug effects; D013926:Thrombopoietin / Q000494:pharmacology / Q000627:therapeutic use*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000925:Anticoagulants; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D000069283:Rituximab; D013926:Thrombopoietin; D000077144:Clopidogrel; C488777:romiplostim; D013988:Ticlopidine; D001241:Aspirin; D011241:Prednisone